LUNGevity is proud to announce our new Patient-Focused Research Center ─ Patient FoRCe. Patient FoRCe, which was launched during the American Association for Cancer Research’s (AACR) Annual Meeting on April 2, is the first-ever critical bridge to connect the voices of lung cancer patients with healthcare professionals, regulators, policymakers, and developers of drugs.
LUNGevity is leading the way to a change in the paradigm of cancer treatment ─ from assuming patient wishes to evidence-based conclusions about what patients value. Patient FoRCe will undertake novel studies of those living with lung cancer, collecting and sharing robust qualitative and quantitative data about lung cancer patients’ preferences and experiences to inform treatment, and relevant policy and research protocols. Patient FoRCe’s immediate focus will include continuing a study of patient preferences and experiences regarding access to care, treatment and diagnostic options, and the impact of symptoms on daily living, as well as conducting studies to facilitate patients’ access to biomarker testing, which is essential to implementing precision medicine. Learn more about Patient FoRCe, its External Advisory Board, and the other work that we are conducting at www.LUNGevity.org/PatientFoRce. |